MDS-445 Magrolimab In Combination With Azacitidine for Patients With Untreated Higher-Risk Myelodysplastic Syndromes (HR MDS): 5F9005 Phase 1b Study Results
Year: 2022
Type: article
Institutions: Moffitt Cancer Center, City Of Hope National Medical Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Roswell Park Comprehensive Cancer Center, Columbia University Irving Medical Center, University of Miami, Sylvester Comprehensive Cancer Center, Tennessee Oncology, University of Colorado Anschutz, University of Colorado Denver, University of California San Diego, Moores Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, Irvine, Gilead Sciences (United States), University of Oxford, MRC Weatherall Institute of Molecular Medicine
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Medical Research Council
Awards: Identification, characterisation and therapeutic targeting of leukaemic stem/propagating cells in Acute Myeloid Leukaemia, Biology and Treatment of Human Myeloid Cancers, University of Oxford – Confidence in Concept 2019, Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours).
OpenAlex ID: W4296468441